Curaleaf Holdings, Inc. (OTCMKTS:CURLF) Given Consensus Rating of “Strong Buy” by Brokerages

Shares of Curaleaf Holdings, Inc. (OTCMKTS:CURLF) have been given an average recommendation of “Strong Buy” by the five ratings firms that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a buy recommendation and three have assigned a strong buy recommendation to the company.

A number of research firms recently issued reports on CURLF. Zacks Research upgraded shares of Curaleaf from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 14th. Citigroup reaffirmed a “buy” rating on shares of Curaleaf in a research note on Thursday.

Curaleaf Price Performance

CURLF stock traded up $0.55 on Thursday, reaching $8.90. The company had a trading volume of 51,593 shares, compared to its average volume of 312,614. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.74 and a current ratio of 1.56. The company’s fifty day moving average is $7.04 and its 200 day moving average is $7.68. The company has a market cap of $2.08 billion, a P/E ratio of -22.82 and a beta of 1.56. Curaleaf has a 1 year low of $4.56 and a 1 year high of $15.15.

Curaleaf (OTCMKTS:CURLF) last released its earnings results on Wednesday, August 5th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.25. The company had revenue of $340.10 million for the quarter, compared to analyst estimates of $332.00 million. Curaleaf had a negative net margin of 7.76% and a negative return on equity of 8.11%. On average, research analysts forecast that Curaleaf will post -0.31 earnings per share for the current year.

Curaleaf Company Profile

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.